Neuromyelitis Optica Devics Syndrome-Pipeline Review, H1 2016

Neuromyelitis Optica Devics Syndrome-Pipeline Review, H1 2016


  • Products Id :- GMDHC7740IDB
  • |
  • Pages: 86
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Neuromyelitis Optica (Devic's Syndrome)-Pipeline Review, H1 2016', provides an overview of the Neuromyelitis Optica (Devic's Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic's Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic's Syndrome)

The report reviews pipeline therapeutics for Neuromyelitis Optica (Devic's Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Neuromyelitis Optica (Devic's Syndrome) therapeutics and enlists all their major and minor projects

The report assesses Neuromyelitis Optica (Devic's Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Devic's Syndrome)

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Neuromyelitis Optica (Devic's Syndrome)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic's Syndrome) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Neuromyelitis Optica (Devic's Syndrome) Overview 8

Therapeutics Development 9

Pipeline Products for Neuromyelitis Optica (Devic's Syndrome)-Overview 9

Pipeline Products for Neuromyelitis Optica (Devic's Syndrome)-Comparative Analysis 10

Neuromyelitis Optica (Devic's Syndrome)-Therapeutics under Development by Companies 11

Neuromyelitis Optica (Devic's Syndrome)-Therapeutics under Investigation by Universities/Institutes 12

Neuromyelitis Optica (Devic's Syndrome)-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Neuromyelitis Optica (Devic's Syndrome)-Products under Development by Companies 16

Neuromyelitis Optica (Devic's Syndrome)-Products under Investigation by Universities/Institutes 17

Neuromyelitis Optica (Devic's Syndrome)-Companies Involved in Therapeutics Development 18

Acorda Therapeutics, Inc. 18

Alexion Pharmaceuticals, Inc. 19

Bionure Farma, S.L. 20

Chugai Pharmaceutical Co., Ltd. 21

Clene Nanomedicine, Inc. 22

HanAll Biopharma Co., Ltd. 23

Karus Therapeutics Limited 24

Marathon Pharmaceuticals, LLC 25

MedImmune, LLC 26

Opexa Therapeutics, Inc. 27

Shire Plc 28

Takeda Pharmaceutical Company Limited 29

Neuromyelitis Optica (Devic's Syndrome)-Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Target 31

Assessment by Mechanism of Action 33

Assessment by Route of Administration 35

Assessment by Molecule Type 37

Drug Profiles 39

ANV-201-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

BN-201-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

C1 esterase inhibitor (human)-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Cellular Immunotherapy for Central Nervous System Disorders-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

CNMAU-8-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

D-15107-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

dalfampridine ER-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

eculizumab-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

HL-161-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

immune globulin (human)-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

inebilizumab-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

KA-1463-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

OPX-212-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

SA-237-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Small Molecule for Neuromyelitis Optica-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Neuromyelitis Optica (Devic's Syndrome)-Recent Pipeline Updates 64

Neuromyelitis Optica (Devic's Syndrome)-Dormant Projects 78

Neuromyelitis Optica (Devic's Syndrome)-Product Development Milestones 79

Featured News & Press Releases 79

Nov 24, 2015: MS Trial Alert: Investigators Recruiting People with Relapsing NMOSD for Study of an Investigational Medicine (Eculizumab) 79

Nov 10, 2015: Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica Program 79

Sep 29, 2015: FDA Approval To Commence Phase I Single Ascending Dose Protocol 80

May 08, 2015: Initiation Of Phase I Clinical Program 80

Apr 20, 2015: Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology 2015 Annual Meeting 80

Apr 15, 2015: Clene Receives IMPD Approval; Phase I Clinical Program Planned 81

Nov 25, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica 81

Sep 08, 2014: Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program 82

Aug 27, 2014: Clene Files Investigational New Drug Application With FDA 82

Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis 83

Appendix 85

Methodology 85

Coverage 85

Secondary Research 85

Primary Research 85

Expert Panel Validation 85

Contact Us 85

Disclaimer 86

List of Figures

Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H1 2016 9

Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome)-Comparative Analysis, H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Number of Products under Investigation by Universities/Institutes, H1 2016 12

Comparative Analysis by Clinical Stage Development, H1 2016 14

Comparative Analysis by Early Stage Products, H1 2016 15

Assessment by Monotherapy Products, H1 2016 30

Number of Products by Top 10 Targets, H1 2016 31

Number of Products by Stage and Top 10 Targets, H1 2016 31

Number of Products by Top 10 Mechanism of Actions, H1 2016 33

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 33

Number of Products by Routes of Administration, H1 2016 35

Number of Products by Stage and Routes of Administration, H1 2016 35

Number of Products by Molecule Types, H1 2016 37

Number of Products by Stage and Molecule Types, H1 2016 37

List of Tables

Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H1 2016 9

Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome)-Comparative Analysis, H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Number of Products under Investigation by Universities/Institutes, H1 2016 12

Comparative Analysis by Late Stage Development, H1 2016 13

Comparative Analysis by Clinical Stage Development, H1 2016 14

Comparative Analysis by Early Stage Development, H1 2016 15

Products under Development by Companies, H1 2016 16

Products under Investigation by Universities/Institutes, H1 2016 17

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Acorda Therapeutics, Inc., H1 2016 18

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Alexion Pharmaceuticals, Inc., H1 2016 19

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Bionure Farma, S.L., H1 2016 20

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016 21

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Clene Nanomedicine, Inc., H1 2016 22

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by HanAll Biopharma Co., Ltd., H1 2016 23

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Karus Therapeutics Limited, H1 2016 24

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Marathon Pharmaceuticals, LLC, H1 2016 25

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by MedImmune, LLC, H1 2016 26

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Opexa Therapeutics, Inc., H1 2016 27

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Shire Plc, H1 2016 28

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 29

Assessment by Monotherapy Products, H1 2016 30

Number of Products by Stage and Target, H1 2016 32

Number of Products by Stage and Mechanism of Action, H1 2016 34

Number of Products by Stage and Route of Administration, H1 2016 36

Number of Products by Stage and Molecule Type, H1 2016 38

Neuromyelitis Optica (Devic's Syndrome) Therapeutics-Recent Pipeline Updates, H1 2016 64

Neuromyelitis Optica (Devic's Syndrome)-Dormant Projects, H1 2016 78

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Acorda Therapeutics, Inc. Alexion Pharmaceuticals, Inc. Bionure Farma, S.L. Chugai Pharmaceutical Co., Ltd. Clene Nanomedicine, Inc. HanAll Biopharma Co., Ltd. Karus Therapeutics Limited Marathon Pharmaceuticals, LLC MedImmune, LLC Opexa Therapeutics, Inc. Shire Plc Takeda Pharmaceutical Company Limited

Neuromyelitis Optica (Devic's Syndrome) Therapeutic Products under Development, Key Players in Neuromyelitis Optica (Devic's Syndrome) Therapeutics, Neuromyelitis Optica (Devic's Syndrome) Pipeline Overview, Neuromyelitis Optica (Devic's Syndrome) Pipeline, Neuromyelitis Optica (Devic's Syndrome) Pipeline Assessment

select a license
Single User License
USD 2000 INR 143840
Site License
USD 4000 INR 287680
Corporate User License
USD 6000 INR 431520

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com